Eribulin

Halaven

賀樂維注射液

1mg/2ml/vial

04. ANTINEOPLASTIC AGENTS; ;

04.09. MISCELLANEOUS;;

Antimicrotubular agent

化學治療劑

C 動物試驗顯示有致畸胎的結果，但沒有針對孕婦或動物有對照組的研究可證明其危險性。

Unknown

IVD/IVF (rate: 2-5 minutes)
1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle Adjustment for Toxicity
Permanently reduce dose from 1.4 mg/m2 to 1.1 mg/m2 for the following:
ANC <500/mm3 for >7 days, ANC <1000/mm3 with fever or infection, Platelets <25,000/mm3, Platelets <50,000/mm3 requiring transfusion, Nonhematologic toxicity of grade 3 or 4, Dose omission or delay due to toxicity on day 8 of prior cycle
Permanently reduce dose from 1.1 mg/m2 to 0.7 mg/m2 for occurrence of any of the above events; discontinue treatment if the above toxicities occur at the 0.7 mg/m2 dose level.

Neutropenia, anemia, fatigue, alopecia, nausea, peripheral neuropathy

1.可未稀釋直接施打或以100ml 0.9%NaCl稀釋。
2.未稀釋之藥品或以0.9%NaCl稀釋後之藥品，於室溫下可存放4小時，於冷藏可存放24小時。未使用完之原瓶需丟棄。
3.勿以葡萄糖溶液稀釋或是用含葡萄糖溶液之靜脈注射管線給藥。
4.勿與其他藥物併用相同之靜脈注射管線給藥。

建立者

103617

建立時間

2018-08-30 10:14:06

維護者

103617

維護時間

2023-02-01 11:50:47